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Grp75Calpains, calcium-dependent cysteine proteases, are involved in a variety of cellular processes. We have
reported on the characteristics of mitochondrial μ-calpain and have shown that ERp57-associated
mitochondrial μ-calpain cleaves the apoptosis-inducing factor (AIF) to a truncated form (tAIF). In addition,
we found an unknown mitochondrial calpain. In this study, we identiﬁed and characterized this undescribed
mitochondrial calpain in rat liver mitochondrial intermembrane space. The mitochondrial μ- and unknown
calpains were separated by DEAE-Sepharose column chromatography. We immunoprecipitated the
unknown calpain with anti-calpain small subunit and identiﬁed it as calpain 2 (m-calpain large subunit)
by nanoﬂow-LC-MS/MS analysis and database searching. Because the identiﬁed mitochondrial calpain was
stained with anti-m-calpain large subunit antibody, we named it mitochondrial m-calpain. The Ca2+
dependency of mitochondrial m-calpain was similar to that of cytosolic m-calpain. Immunoprecipitation
analyses showed that mitochondrial m-calpain is associated with a 75-kDa glucose-regulated protein, a
member of the heat shock protein 70 family. We also investigated the involvement of mitochondrial m-
calpain in the release of tAIF from mitochondria. Calpain inhibitor, PD150606, an anti-voltage-dependent
anion channel (VDAC), and anti-Bax antibodies prevented the release of tAIF from mitochondria. In addition,
we found that mitochondrial m-calpain truncated VDAC in Ca2+-dependent manner. This cleavage of VDAC
promotes the mitochondrial accumulation of Bax and the release of tAIF from mitochondria. The
accumulated Bax in mitochondrial outer membrane was co-immunoprecipitated with VDAC. Our results
demonstrated that mitochondrial m-calpain plays a role in the release of tAIF from mitochondria by cleaving
VDAC, and tAIF is released through VDAC-Bax pores.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The calpains (E.C. 3.4.22.17) form a superfamily of intracellular
cysteine proteases with numerous isoforms that are found in almost
all eukaryotes and some bacteria [1–4]. At present, 14 human genes
have been identiﬁed as members of the calpain catalytic subunit
family and two genes identiﬁed for calpain regulatory subunits
[4,5]. Although their physiological roles have not been fully
determined, they function in Ca2+ signaling by modulating thetruncated AIF; VDAC, voltage-
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[5].
The calpain family can be divided into the ubiquitous and the
tissue-speciﬁc calpains [4]. Two major ubiquitous calpains, viz. μ-
calpain and m-calpain large catalytic subunits (molecular mass,
∼80 kDa), are associated with a common regulatory small subunit
(molecular mass, ∼30 kDa) [2]. The μ- and m-calpains share about
62% identical residues of their catalytic subunits and differ in the
Ca2+ concentrations required for their activation in vitro; μ- and m-
calpains are activated by 5–50 μM and 0.2–1 mM Ca2+, respectively.
These two calpains have a speciﬁc endogenous inhibitor, calpastatin
[6–9]. Knockout of the μ-calpain large subunit gene results in viable
mice with reduced platelet aggregation and impaired tyrosine
phosphorylation in the platelets [10]. Knockout of the m-calpain
large subunit is embryonically lethal [11,12].
Although calpains are considered to be cytoplasmic enzymes, we
have shown that calpains also exist in the mitochondria and are
involved in the truncations of mitochondrial aspartate aminotrans-
ferase (AAT) and apoptosis-inducing factor (AIF) [13–15]. The bio-
chemical characteristics of mitochondrial μ-calpain are similar to
cytosolic μ-calpain [14], and ERp57 chaperone associates with
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associated mitochondrial μ-calpain cleaves AIF to a truncated form,
tAIF, and releases it from the mitochondrial inner membrane (IM)
into the intermembrane space (IMS). Recently, other investigators
also reported that μ-calpain is present in the mitochondria [16–19].
It is becoming increasingly apparent that calpain 10 exists in the
mitochondria and is involved in calcium-induced mitochondrial
dysfunction by its cleavage of Complex I subunits of the electron
transport chain [20].
However, we and other investigators expected that one or more
unidentiﬁed calpains exist in the mitochondria. Beer et al. [21]
suggested that two Ca2+-activated proteases exist in rat liver
mitochondria, one was half-maximally activated with 25 μM Ca2+
and the other by 750 μM Ca2+. Furthermore, Tavares et al. [22] found
two calpain activities in the IMS and three in the matrix. In our
earlier study, we found two types of mitochondrial calpains by casein
zymography; one is mitochondrial μ-calpain and the other is an
unknown mitochondrial calpain [14,15]. We also demonstrated that
the unknown mitochondrial calpain is associated with a regulatory
small subunit. Calpastatin is not present in the mitochondria, so we
expected that the unknown mitochondrial calpain is associated with
an unidentiﬁed regulatory molecule such as ERp57.
AIF, one of the apoptosis-related proteins, is known to be a key
factor in caspase-independent apoptosis [23]. It is anchored to the
outer face of the mitochondrial IM and its proteolytic processing by
mitochondrial μ-calpain is required to become a soluble and apop-
togenic protein [14,15,24]. The released tAIF frommitochondria to the
cytosol translocates into nucleus where it causes chromatin con-
densation and large scale (∼50 kb) DNA fragmentation in a caspase-
independent fashion [25,26]. This apoptogenic function of AIF seems
essential in some types of cell death. In fact, AIF seems to be implicated
in retinal degeneration in eyes with retinitis pigmentosa [27,28] and
brain neuronal injury including hypoxia and ischemia [16,29].
However, the mechanisms that cause the release of tAIF from
mitochondrial IMS into the cytoplasm have not been determined. We
considered that the inhibition of the release of tAIF frommitochondria
can prevent these tAIF-mediated insults.
The purpose of this study was to identify the unknown mito-
chondrial calpain and its regulatory molecules and to examine its
functions in themitochondria. We tested whether the unknownmito-
chondrial calpain plays a role in the release of tAIF frommitochondria.
2. Materials and methods
2.1. Materials
Antibodies purchased were rabbit polyclonal antibodies against μ-
calpain large subunit domain IV (Sigma Aldrich Corp., St. Louis, MO);
anti-m-calpain large subunit domain I, III, and IV (Abcam, Inc.,
Cambridge, MA); anti-calpain small subunit domain V (Abcam); anti-
calpain 10 domain T (Sigma Aldrich); anti-Grp75 (Santa Cruz Bio-
technology Inc., CA); anti-adenylate kinase 2 (Santa Cruz); anti-
glyceraldehyde phosphate dehydrogenase (Santa Cruz); anti-VDAC
(Calbiochem); anti-Bax (Abcam); anti-AIF (Abcam); anti-pyruvate
dehydrogenase (Molecular Probes, Eugene, OR); goat polyclonal anti-
VDAC C-terminal (Santa Cruz);mousemonoclonal anti-TGN-38 (trans-
Golgi network-38) (Abcam); rat monoclonal anti-ZO-1 (Chemicon,
Temecula, CA); and normal rabbit IgG (Santa Cruz). Anti-VDAC anti-
body recognizes amino acid residues 185–197 of human VDAC. Rabbit
anti-ERp57 antiserum was prepared against the 17-amino acid C-
terminal peptide (VIQEEKPKKKKKAQEDL) of human ERp57 as
described [30]. Rabbit anti-calnexin antiserawere obtained asdescribed
[31]. Calpain inhibitors, calpeptin and PD150606, were purchased from
Calbiochem (Cambridge, MA), and VDAC inhibitor, DIDS (4,4′-
diisothiocyanostilbene-2,2′-disulfonic acid), was purchased from
Sigma Aldrich.2.2. Preparation of rat liver mitochondria and submitochondrial
fractionations
Rat liver mitochondria and mitochondrial compartments were
prepared as described in detail [14]. To obtain mitochondrial un-
known calpain, the mitochondrial IMS fraction was prepared from 30
Sprague–Dawley rats (8 weeks old). The purity of the mitochondrial
compartments was determined by immunoblot analysis with the
following antibodies; anti-mitochondrial porin (VDAC) antibody for
mitochondrial outer membrane (OM), anti-adenylate kinase 2 (AK2)
for intermembrane space (IMS), anti-AIF antibody for inner mem-
brane (IM), pyruvate dehydrogenase (PDH) antibody for matrix, anti-
glyceraldehyde phosphate dehydrogenase (GAPDH) antibody for
cytosolic fraction, anti-ZO-1 (tight junction-associated protein) for
plasma membrane, anti-calnexin for ER, and anti-TGN-38 for Golgi
apparatus. High purities of the mitochondrial compartments were
obtained.
2.3. Partial puriﬁcation of mitochondrial unknown calpain
A partial puriﬁcation of mitochondrial unknown calpain was
accomplished by DEAE-Sepharose CL-6B (Amersham Pharmacia
Biotech) column chromatography. All chromatographic procedures
were performed at 4 °C. The prepared IMS fraction was dialyzed
overnight against 2 L of buffer A (20 mM Tris–HCl, pH 7.5, 1 mM
EDTA, 1 mM EGTA, and 5 mM 2-mercaptoethanol) containing 50 mM
NaCl (buffer B) at 4 °C. The dialyzed proteins were applied to a
DEAE-Sepharose CL-6B column (26.4×400 mm) pre-equilibrated
with buffer B at a ﬂow rate of 1.0 ml/min. The fraction size was
10 ml/tube. Aliquots (50 μl) of the fractions were used to assay for
calpain activity as described [14]. Unbound proteins, containing
mitochondrial unknown calpain, were eluted with 600 ml of buffer B.
Mitochondrial μ-calpain was eluted with a linear gradient of 50–
250 mM NaCl in buffer A in a total volume of 1.2 L. Four activity
peaks, unbounded protein fraction at 120 mM NaCl, at 150 mM NaCl,
and at 200 mM NaCl, were detected. The fractions containing calpain
activity were collected and concentrated by Amicon PM-10 mem-
brane (Millipore Co., Bedford, MA). The concentrates were used for
western blot analyses with anti-μ-calpain, m-calpain large subunits,
anti-calpain small subunit, anti-ERp57, and anti-calpain 10 anti-
bodies and for calpain assay using EGTA and calpain inhibitors. The
protein concentration was measured by the method of Bradford et al.
[32] with bovine serum albumin as the standard.
2.4. Western blotting
Western blotting was performed as described in detail [14,15].
After electrophoretic transfer of the proteins to a nitrocellulose
membrane, the membranes were treated with the primary antibodies
followed by horseradish peroxidase (HRP)-conjugated goat anti-
rabbit or rabbit anti-goat IgG secondary antibodies (DAKO, Cam-
bridge, UK). Immunoreactive signals were developed with an ECL
western blotting detection kit (Amersham Biosciences) and quanti-
ﬁed with a Luminescent Image Analyzer, LAS-3000 (Fujiﬁlm Co.,
Tokyo, Japan).
2.5. Immunoprecipitation of mitochondrial unknown calpain
A rabbit polyclonal anti-calpain small subunit antibody was used
to immunoprecipitate mitochondrial unknown calpain. We added the
antibody (1 μg/tube) to calpain activity peak 1 pooled from DEAE-
Sepharose CL-6B column chromatography (1 mg protein/tube),
which contained mitochondrial unknown calpain, in a total volume
of 500 μl of buffer B. After standing at 4 °C for 18 h, excess protein G-
Sepharose 4 Fast Flow (Amersham Pharmacia Biotech) was added
(12 μl/tube) and allowed to stand for another 2 h at 4 °C. The sample
1850 T. Ozaki et al. / Biochimica et Biophysica Acta 1793 (2009) 1848–1859was centrifuged at 12,000 rpm for 5 min at 4 °C. The precipitates were
washed six times with 50 mM Tris–HCl, pH 7.4, containing 0.5 M NaCl
and 0.1% Emulphogen BC 720. Co-immunoprecipitated proteins with
anti-calpain small subunit were subjected to SDS–PAGE, in-gel
digestion, and identiﬁed by nanoﬂow-LC-MS/MS analyses.
2.6. Preparation of tryptic peptides for nanoﬂow-LC-MS/MS analyses
The protein bands on the silver stained gels were excised, and in-
gel tryptic digestion was carried out according to Hellman et al. [33]
with slight modiﬁcations as described [15]. The tryptic peptides
were dissolved in 20 μl of 0.1% triﬂuoroacetic acid (TFA) and
desalted by passing through C18 ZipTip (Millipore, Bedford, MA).
ZipTip was wetted and equilibrated with 50% acetonitrile, 0.1% TFA
containing 75% acetonitrile, and 0.1% TFA in that order. The peptide
solution was absorbed to ZipTip for 20 times. The ZipTip was washed
with 0.1% TFA. The peptides were eluted with 10 μl of 75%
acetonitrile/0.1% TFA. The peptide solution was dried in vacuo and
stored at –20 °C until analyzed.
2.7. Nanoﬂow-LC-MS/MS analyses
The peptides were dissolved in 20 μl of 0.1% formic acid (FA).
Peptide digests were loaded onto a C18 capillary column
(75×100 mm, GL sciences, Tokyo, Japan) equilibrated with 2%
acetonitrile/0.1% FA. The adsorbed peptides were eluted with a linear
gradient of buffer C (2% acetonitrile/0.1% FA) and buffer D (98%
acetonitrile/0.1% FA) at a ﬂow rate of 200 nl/min (2–40% Buffer D for
60 min; 40–100% Buffer D for 3 min; then 100% Buffer D for 20 min).
Mass spectrometry was performed with a NanoFrontier LD massFig. 1. Partial puriﬁcation of the unknownmitochondrial calpain. (A) Casein zymogram for m
andmitochondrial IMS (100 μg). Erythrocytes were used as a positive control for μ-calpain (la
calpain was shifted upward and becameweaker by pre-treatment with anti-ERp57 antibody
IMS. Details are described in the Materials and methods section. Four peaks of calpain-like ac
(Peak 2), third at 150 mMNaCl (Peak 3), and fourth at 200 mMNaCl (Peak 4). (C) Western b
antibodies used were anti-μ-calpain large subunit, calpain small subunit, ERp57, and calpain
anti-calpain small subunit antibody. Peaks 2 and 3 were stainedwith anti-μ-calpain large sub
(D) Effects of Ca2+ and calpain inhibitors on each of the calpain-like activity peaks. Assay of e
Ca2+. Calpeptin and PD150606 were pre-treated as described in Materials and methods s
inhibited by calpeptin and PD150606. The activity of peak 3 was inhibited strongly by calpep
PD150606. The activity in peak 4 was Ca2+ independent and inhibited strongly by calpeptin
Results are representative of ﬁve independent experiments.spectrometer in a data-dependent fashion as peptides were eluted off
of the capillary column (Hitachi High-Technologies Corp., Tokyo). A
mass range of 100–2000 was implemented for all runs.
2.8. Analyses of nanoﬂow-LC-MS/MS data and database searching
The MS/MS data underwent de novo sequencing and searched
against the species-speciﬁc component of the NCBInr database using
PEAKS Studio (Infocom corp., Tokyo). Two missed cleavages were
allowed. A ﬁxed modiﬁcation of carbamidomethylation for cysteine
was used. A parent mass window of 0.5 and a fragment tolerance of
0.5 were used for all ion trap based searches. A charge state of +2
and +3 was speciﬁed for all nanospray analyses.
2.9. RNA isolation and complementary DNA preparation
Total RNA was isolated from Sprague–Dawley rat (8 weeks old,
female) liver using ISOGEN reagent according to the supplier's
instructions (Nippon Gene, Toyama, Japan). The RNA concentration
was determined by measuring the absorbance at 260 nm. Total RNA
was stored at −80 °C until use. To synthesize complementary DNA
(cDNA) synthesis, 4 μg of total RNA was reverse transcribed using
AMV reverse transcriptase (Life Sciences, St. Petersburg, FL) and
oligo(dT)20.
2.10. Ampliﬁcation of Capn2 cDNA fragments by PCR
PCR was performed using Taq DNA Polymerase (Takara, Osaka,
Japan) and the above cDNA as templates. The sense and antisense
primers for the rat Capn2 (calpain 2 gene) were 5′-TCCTGAGGCAC-itochondrial calpains. Samples used were rat erythrocytes (50 μg), liver cytosol (50 μg),
ne 1). Two active bands were detected in the IMS (lane 3). The band of mitochondrial μ-
(lane 4). (B) DEAE-Sepharose CL-6B column chromatogram of mitochondrial calpains of
tivity are present; ﬁrst at unbounded protein fractions (Peak 1), second at 120 mMNaCl
lot analysis of each peak of calpain-like activity (40 μg/lane). From top to bottom panel,
10 antibodies. IMS fraction (20 μg) was used as a control. Peak1 was stained only with
unit and calpain small subunit antibodies. Peak 3 was stained with anti-ERp57 antibody.
ach calpain peak (25 μg/reaction mixture) was performed in the presence or absence of
ection. Peaks 1 and 2 were activated in a Ca2+-dependent manner and were strongly
tin, however, 40% of the activity was Ca2+ independent and only 50% was inhibited by
and moderately by PD150606, respectively. Data are expressed as means±SD, n=3.
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sequence) and 5′-GTTGGCCTCGATTTCATCAT-3′ (positions 1544–
1563), respectively (Nihon gene research laboratories, Sendai,
Japan). Both primers contained portions of the 5′- and 3′-
untranslated regions. The PCR cycling conditions were 95 °C for
4 min, followed by 30 cycles at 95 °C for 30 s, 52 °C for 30 s, and
72 °C for 1 min, followed by a 7-min ﬁnal extension at 72 °C. The
ampliﬁed PCR products were run on 6% acrylamide or 1.5% agarose
gels to conﬁrm correct sizes (Predicted Size: 572 bp).
2.11. Cloning of Capn2 PCR products and nucleotide sequencing
PCR products of rat Capn2 were electrophoresed on 1.5% agarose
gels. The DNA was extracted and puriﬁed from the agarose gels
using Geneclean kit (BIO 101, Inc., Vista, CA). The puriﬁed DNA
were subcloned into pT7Blue T-Vector and transformed into
Escherichia coli XL1-Blue competent cells according to the supplier's
protocol (Novagen, Madison, WI). The plasmid DNA were extracted
from the bacterial cells and the puriﬁed plasmid DNAs were cut
with the restriction enzymes EcoRI and HindIII. The fragments were
electrophoresed on 1% agarose gels to conﬁrm the insertions of
DNAs. The nucleotide sequence was determined using a Big Dye
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosys-
tems, Foster City, CA) and ABI PRISM DNA sequencer 310 (Applied
Biosystems). DNA sequence data were analyzed using Hitachi
DNASIS Software. The nucleotide sequence of rat Capn2 was sub-
mitted to GenBank under accession no. L09120.
2.12. Proteinase K treatment
To examine whether mitochondrial m-calpain exists in the outer
or inner face of the outer mitochondrial membrane, the mitochon-Fig. 2. Immunoprecipitation, nanoﬂow-LC-MS/MS analyses of unknown mitochondrial calp
Sepharose column chromatogram with anti-calpain small subunit and subjected to SDS–PA
band was excised, subjected to in-gel tryptic digestion and nanoﬂow-LC-MS/MS (open arr
79,919) at a coverage of 4%. The identities of these peptides are indicated as shaded sequen
synthetase 1, glutamate oxaloacetate transaminase 2, immunoglobulin gamma-2a chain,
independent experiments.drial surface was treated with proteinase K following the method of
Gao et al. [34]. Isolated rat liver mitochondria were suspended in
homogenizing buffer (20 mM Tris–HCl, pH 7.5, containing 1 mM
EDTA, 1 mM EGTA, 0.25 M sucrose, and 5 mM 2-mercaptoethanol)
and treated with proteinase K (Sigma) at a ﬁnal concentration of
50 μg/ml for 30 min at 4 °C. Phenylmethylsulfonyl ﬂuoride (PMSF,
Sigma) was then added to a ﬁnal concentration of 2 mmol/liter, and
samples were incubated for a further 10 min at 4 °C. Mitochondria
were reisolated by centrifugation at 10,000×g for 10 min at 4 °C.
Then, western blot analysis was performed with anti-m-calpain large
subunit (domain IV) antibody.
2.13. Ca2+ dependency of mitochondrial m-calpain
The Ca2+ requirements of the calpains were determined by a
Ca2+-EGTA buffer system [22]. Each sample (50 μg protein) was
added to 450 μl of assay buffer (100 mM Tris–HCl, pH 7.5,
10 mM 2-mercaptoethanol, 100 mM KCl, 1 mM EGTA, 20 μM
Succ-Leu-Tyr-AMC) in the presence of different concentrations of
CaCl2 (0–1000 μM).
2.14. Casein zymography
Zymographic analysis was carried out according to Raser et al. [35]
and Arthur et al. [36] with slight modiﬁcations as described [15].
2.15. Analyses of Grp75-mitochondrial m-calpain interaction
using immunoprecipitation
The polyclonal antibody to Grp75 (1 μg) and m-calpain large
subunit domain IV (1 μg) were incubated with 500 μl preparation
(300 μg protein) of DEAE-Sepharose puriﬁed mitochondrial m-ain. (A) Unknown mitochondrial calpain was immunoprecipitated in Peak 1 of DEAE-
GE silver staining (Lane I.P.). Lane M, molecular weight standards. The 75-kDa protein
owhead). (B) Four peptides matched with rat calpain 2 (m-calpain large subunit, MW
ces. (C) Bands other than the 75-kDa protein were identiﬁed as carbamoyl-phosphate
and electron transferring ﬂavoprotein (arrows). Results are representative of three
1852 T. Ozaki et al. / Biochimica et Biophysica Acta 1793 (2009) 1848–1859calpain in buffer A (20 mM Tris–HCl, pH 7.5, 1 mM EDTA, 1 mM
EGTA and in 5 mM 2-mercaptoethanol) containing 140 mM NaCl.
After standing for 18 h at 4 °C, excess protein G-Sepharose 4 Fast
Flow was added (12 μl/tube), and allowed to stand for 2 h at 4 °C.
The sample was centrifuged at 12,000 rpm for 5 min at 4 °C. The
pellet was washed six times with 50 mM Tris–HCl, pH 7.4,
containing 140 mM NaCl and 0.1% Emulphogen BC 720. Co-
immunoprecipitated proteins were analyzed by western blot
analyses with anti-m-calpain large subunit, anti-calpain small
subunit, and anti-Grp75 antibodies, respectively.
2.16. Effects of anti-VDAC, anti-Bax, calpain inhibitor, and VDAC
inhibitor on release of tAIF from mitochondria
Isolated mitochondria from two Sprague–Dawley rat (8 weeks
old) livers were placed in resuspending buffer (20 mM Tris–HCl,Fig. 3.Western blot analysis with anti-m-calpain antibody. (A) Reactivities of DEAE-Sepharo
4), and IV (lane 6). Each sample contained 40 μg of protein. DEAE-Sepharose puriﬁed cytoso
unknown calpain is stained by anti-m-calpain domains I and IV, but not by domain III. We nam
m-calpain domain III. Ampliﬁcations were performed with one pair of primers targeting the
marker; Capn2 III: PCR product of Capn2 domain III using total RNA of rat liver; NC: negat
(arrowhead). We conﬁrmed the sequences of the PCR products and found that the PCR
mitochondrial m-calpain with the use of anti-m-calpain domain IV antibody. Each sample co
lane). Mitochondrial m-calpain was present mainly in mitochondrial outer membrane (O
compartments was determined with the appropriate antibody to marker protein [VDAC, OM
ER; TGN-38; Golgi apparatus] (40 μg/lane). (D) Western blot analysis of proteinase K-trea
treated with proteinase K as described in the Materials and methods section. Cytosolic fractio
2, 10 μg/lane). Mitochondrial m-calpain was detected after proteinase K treatment of the
independent experiments.pH 7.5, 0.25 M sucrose, and 5 mM 2-mercaptoethanol) supple-
mented with 50 μM CaCl2 and incubated at 30 °C for 30 min. After
incubation, the mitochondrial suspension was allowed to stand at
4 °C for 1 h in the presence or absence of cytosolic fraction without
μ- and m-calpains, which were removed by DEAE-Sepharose CL-6B
column chromatography (9.2 mg protein/ml), 20 μM PD150606
(calpain inhibitor), 0.5 mM DIDS (VDAC inhibitor), rabbit poly-
clonal anti-VDAC, goat polyclonal anti-VDAC (C-terminal) antibody,
rabbit polyclonal anti-Bax antibodies, and normal rabbit IgG (40 μg
IgG/10 mL suspensions). Then samples were supplemented with
1 mM CaCl2 and incubated at 30 °C for 30 min. The samples were
centrifuged at 10,000×g for 10 min at 4 °C. The supernatant con-
taining the released proteins from the mitochondria was used for
western blotting to determine whether tAIF was released. The
mitochondrial compartments were separated from mitochondrial
pellet as described [14].se puriﬁed unknown mitochondrial calpain with m-calpain domains I (lane 2), III (lane
lic m-calpain was used as a positive control (lanes 1, 3, and 5, 5 μg/lane). Mitochondrial
ed the identiﬁedmitochondrial calpain, “mitochondrial m-calpain”. (B) PCR analysis of
m-calpain domain III region as described in the Materials and methods section. M: DNA
ive control (PCR product without no cDNA). Only one band was detected at ∼570 bp
products were those of m-calpain domain III. (C) The mitochondrial localization of
ntained 40 μg of protein. Cytosolic fraction was used as a positive control (lane 5, 10 μg/
M, lane 1) and intermembrane space (IMS, lane 2). The purity of the mitochondrial
; AK2, IMS; AIF, IM; PDH, Matrix; GAPDH, Cytosol; ZO-1, plasma membrane; Calnexin,
ted mitochondria with anti-m-calpain domain IV antibody. Isolated mitochondria was
n was used as a positive control to conﬁrm that proteinase K was activated (lanes 1 and
mitochondrial surface (lanes 3 and 4, 40 μg/lane). Results are representative of three
Fig. 4. Casein zymogram and calcium requirement of mitochondrial m-calpain. (A)
Samples used for casein zymography were rat erythrocytes, liver cytosol, and DEAE-
Sepharose puriﬁed mitochondrial m-calpain. Each sample contained 50 μg of protein.
The mitochondrial m-calpain has a higher mobility than cytosolic m-calpain (open
arrowhead). Results are representative of three independent experiments. (B)
Calcium requirements of DEAE-Sepharose puriﬁed-cytosolic μ-, m-calpains, mito-
chondrial μ- and m-calpains (25 μg/reaction mixture) for hydrolysis. Assay of calpain
hydrolytic activity was performed at different Ca2+ concentrations. Calcium
dependency of mitochondrial m-calpain (■) is similar to that of cytosolic m-calpain
(□). Data are expressed as means±SD, n=3.
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Mitochondrial outer membrane (OM) prepared from Sprague–
Dawley rat (8 weeks old) liver was suspended in 20 mM Tris–HCl, pH
7.5, and 5 mM 2-mercaptoethanol. We added partially puriﬁed
cytosolic μ-, m-calpains, mitochondrial μ-, and m-calpains (10 μg
each) to the OM (30 μg). Each sample was incubated for 30 min at
30 °C in the presence or absence of 1 mM CaCl2, 5 mM EGTA, and
10 μM PD150606. After incubation, we determined the proteolytic
products of VDAC by western blotting.
2.18. Effects of Ca2+ concentration on activation of mitochondrial
m-calpain, processing of VDAC, accumulation of Bax in mitochondrial
OM, and release of tAIF from mitochondria
Isolatedmitochondria from two Sprague–Dawley rat (8weeks old)
livers were incubated in resuspending buffer (20mMTris–HCl, pH 7.5,
0.25 M sucrose and 5 mM 2-mercaptoethanol) with different
concentrations of CaCl2 (0–1000 μM). The mitochondrial suspension
was allowed to stand for 1 h at 4 °C in the presence of cytosolic fraction
without μ- and m-calpains, which were removed by DEAE-Sepharose
CL-6B column chromatography (9.2mg protein/ml). Each sample was
incubated at 30 °C for 1 h and centrifuged at 10,000×g for 10 min at
4 °C. The supernatant containing the released proteins from mito-
chondria was used for western blotting to determine the mitochon-
drial release of tAIF. The mitochondrial pellets were separated into
mitochondrial compartments as described [14]. Using the IMS and OM
fractions, we determined the activation/autolysis of mitochondrial m-
calpain in the IMS, proteolytic processing of VDAC in the OM, and
accumulation of Bax on the OM by western blotting.
3. Results
3.1. Partial puriﬁcation of unknown mitochondrial calpain
Casein zymography was used to conﬁrm the presence of an
unknown mitochondrial calpain. We found two types of mitochon-
drial calpains; an upper band for mitochondrial μ-calpain and a
lower band for the unidentiﬁed mitochondrial calpain (Fig. 1A).
We used DEAE-Sepharose CL-6B column chromatography to
separate the unknown mitochondrial calpain from mitochondrial
μ-calpain in rat liver mitochondrial IMS (Fig. 1B). The unbound
proteins were eluted with buffer A containing 50 mM NaCl, and
the adsorbed proteins were eluted with a linear gradient of 50–
250 mM NaCl in buffer A.
We found four peaks of calpain activity; an unbound protein
fractions (Peak 1), at 120 mM NaCl (Peak 2), at 150 mM NaCl
(Peak 3), and at 200 mM NaCl (Peak 4). Each peak was collected
and concentrated.
Then we investigated which peaks contained the unknown mito-
chondrial calpain. We performed western blot analyses and
determined the Ca2+ requirement for calpain activation and
susceptibilities of each calpain peak to calpain inhibitors. Western
blot analyses showed that the μ-calpain large subunits were
contained in peaks 2 and 3, calpain small subunits in peaks 1–3,
and ERp57 in peak 3. Calpain 10 was not present (Fig. 1C). The upper
and lower bands of μ-calpain large subunit revealed the pre-active
(intact) and active (autolytic) forms, respectively. The calpain
activities of peaks 1 and 2 were Ca2+ dependent and inhibited by
calpain inhibitors, calpeptin, and PD150606 (Fig. 1D). Sixty percent
of the calpain activity in Peak 3 was Ca2+ dependent and only 50% of
the activity was inhibited by PD150606.
The calpain activity in peak 4 was Ca2+ independent and was
strongly inhibited by calpeptin and moderately by PD150606. These
results suggested that peak 1 contained the unknown mitochondrial
calpain, peak 2 contained mitochondrial μ-calpain, peak 3 containedERp57-associated mitochondrial μ-calpain and unknown proteases
except calpains, and peak 4 contained unknown proteases except
calpains.
3.2. Immunoprecipitation and SDS–PAGE analyses of unknown
mitochondrial calpain
Anti-calpain small subunit was used to immunoprecipitate the
unknown mitochondrial calpain in peak 1 isolated by DEAE-
Sepharose CL-6B column chromatography. The immunoprecipitated
proteins were analyzed by SDS–PAGE and silver staining (Fig. 2A).
We detected eight clear bands of proteins except the IgG heavy
and light chains. We predicted that the 75-kDa protein represented
the large subunit of unknown mitochondrial calpain.
3.3. Identiﬁcation of unknown mitochondrial calpain by
nanoﬂow-LC-MS/MS analyses
To identify the unknown mitochondrial calpain, the 75-kDa
protein and other protein bands were excised from the gel and
subjected to in-gel tryptic digestion and nanoﬂow-LC-MS/MS
analyses. Tryptic fragments of the 75-kDa protein was identiﬁed
as calpain 2 (m-calpain large subunit, MW 79,919) at a coverage of
4% on MS score of 93% and a 75-kDa glucose-regulated protein
(Grp75, MW 73,731) at a coverage of 7% on MS score of 92%. The
MS score of an identiﬁed protein is a probability score which is
derived from the scores of the supported peptides. Usually, proteins
with scores great than 60% are statistically signiﬁcant. The “Peaks
reference” can be found at http://www.bioinformaticssolutions.
com/dbpostings/bsipapers.php. There were 4 peptides identiﬁed in
the 75-kDa band, that were contained within the amino acid
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were; 334HYS336, 404GCTFLVGLIQK414, 451NFFLTTR457 in domain III,
and 579IMVDMLDEDGSGK591 in domain IV (Fig. 2B, shaded sequence).
The MS/MS spectra of these peptides were shown in the “Supple-
mental data”. The nanoﬂow-LC-MS/MS analyses of the other bands
except the 75-kDa protein, identiﬁed carbamoyl-phosphate synthe-
tase 1, glutamate oxaloacetate transaminase 2, immunoglobulin
gamma-2a chain, and electron transferring ﬂavoprotein (Fig. 2C).
3.4. Western blot analyses of identiﬁed mitochondrial m-calpain
We performed western blot analyses with anti-m-calpain large
subunit domains I, III, and IV on partial puriﬁed unknown
mitochondrial calpain, which has an amino acid sequence homology
with m-calpain large subunit. The results showed that the unknown
mitochondrial calpain was positive to anti-m-calpain domain I and
IV, but not to anti-m-calpain domain III (Fig. 3A). Therefore, we call
the unknown mitochondrial calpain “mitochondrial m-calpain”.
To conﬁrm the presence of alternative splicing variant(s) of m-
calpain large subunit, we isolated total RNA from Sprague–Dawley rat
liver, synthesized cDNAs, and performed PCR analysis of Capn2
containing the domain III region. PCR analysis was performed using
gene-speciﬁc primers based on rat sequences for Capn2 (m-calpain
large subunit gene) as described in Materials and methods section.
PCR analysis showed that PCR product was seen as one band. The
572 bp band corresponded to the PCR product coding m-calpain
domain III. This indicated that the rat Capn2 nucleotides coding m-
calpain large subunit domain III has not deleted in large portion. Then
we performed the cloning of Capn2 PCR products and nucleotide
sequencing. We picked up 9 clones and analyzed the sequences. The
sequence analysis showed that nucleotide sequences of 9 clones wereFig. 5. Interaction between Grp75 andmitochondrial m-calpain. (A) Mitochondrial distributio
loaded with 20 μg of protein. Grp75 is present in all mitochondrial compartments. (B) Im
described in the Materials and methods section. Both mitochondrial m-calpain large (open
Immunoprecipitation of Grp75 with anti-m-calpain domain IV antibody. Grp75 is co-pre
representative of three independent experiments.matched with that of rat Capn2 domain III region (data not shown).
And we could not detect an obvious deletion and replacement of the
Capn2 domain III.
Western blot analysis using anti-m-calpain domain IV in mito-
chondrial compartments showed that the mitochondrial m-calpain
is located mainly in the mitochondrial OM and IMS (Fig. 3C).
Subfractions of mitochondria were identiﬁed by the appropriate
antibody to marker proteins: VDAC for OM, AK2 for IMS, AIF for
IM, PDH for matrix, GAPDH for cytosol, ZO-1 for plasma mem-
brane, Calnexin for ER, and TGN-38 for Golgi apparatus. High
purities of the mitochondrial compartments can be seen.
Proteinase K treatment has been used extensively to selectively
remove proteins from the outer surface of mitochondrial OM. After
proteinase K treatment of the mitochondrial surface, mitochondrial
m-calpain large subunit was still localized in mitochondrial fraction
(Fig. 3D).
3.5. Casein zymography and calcium requirement of mitochondrial
m-calpain
Casein zymography of DEAE-Sepharose puriﬁed mitochondrial m-
calpain revealed one band. The mobility of this active band was
different from cytosolic μ- and m-calpains and had higher mobility
than cytosolic m-calpain (Fig. 4A). The dependency of mitochondrial
m-calpain on calcium was similar to cytosolic m-calpain (Fig. 4B).
3.6. Interaction of mitochondrial m-calpain with Grp75
We identiﬁed Grp75 or mitochondrial heat shock 70-kDa protein
in a partially puriﬁed preparation of mitochondrial m-calpain by
nanoﬂow-LC-MS/MS analyses. Western blot analyses using anti-n of Grp75. Cytosolic fractionwas used as a negative control (lane 5), and each lane was
munoprecipitation of mitochondrial m-calpain with anti-Grp75 antibody. Details are
arrowhead) and small subunits (solid arrowhead) are co-precipitated with Grp75. (C)
cipitated with mitochondrial m-calpain large subunit (open arrowhead). Results are
1855T. Ozaki et al. / Biochimica et Biophysica Acta 1793 (2009) 1848–1859Grp75 antibody showed that Grp75 was present in the mitochon-
drial compartments (Fig. 5A). We used immunoprecipitation to
determine whether Grp75 was associated with mitochondrial m-
calpain. Mitochondrial m-calpain large and small subunits were
immunoprecipitated with anti-Grp75 antibody (Fig. 5B). Similarly,
Grp75 was immunoprecipitated with anti-m-calpain large subunit
antibody (Fig. 5C). These results suggested that Grp75 was asso-
ciated with mitochondrial m-calpain.
3.7. Effects of anti-VDAC, anti-Bax, calpain inhibitors, and VDAC inhibitor
on the release of tAIF from mitochondria
We investigated whether mitochondrial m-calpain plays a role in
the release of tAIF from mitochondria. Initially, we activated
mitochondrial μ-calpain and proteolytic processing of AIF in isolated
mitochondria with 50 μM Ca2+. We detected tAIF in the IMS and an
activation of mitochondrial μ-calpain, which resulted in a disappear-
ance of its caseinolytic active band at 50 μM Ca2+ (Figs. 6A and B).
Then, we added 1 mM Ca2+ to the isolated mitochondria, which
activated the mitochondrial m-calpain.
We examined the effects of PD150606 (calpain inhibitor), DIDS
(VDAC inhibitor), anti-VDAC, and anti-Bax antibodies on releasingFig. 6. Effects of anti-VDAC, anti-Bax, calpain inhibitor, and VDAC inhibitor on the release of t
lanewas loadedwith 40 μg of protein. To investigate whether mitochondrial m-calpain, VDAC
μ-calpain with 50 μM Ca2+ to promote proteolytic processing of AIF in the isolated mitocho
experiments. (A) Western blot analysis showed that ∼62-kDa AIF (solid arrowhead) was tru
facilitated at 1 mM Ca2+. (B) Casein zymogram showing the active band of mitochondrial μ-
tAIF from mitochondria. Next we added 1 mM Ca2+ to pre-treated mitochondria with 50
determined the effects of PD150606 (calpain inhibitor), DIDS (VDAC inhibitor), anti-VDA
cytosolic fraction after removing μ- andm-calpains by DEAE-Sepharose column chromatogra
proteins (lane 1), and cytosolic proteins induced the release of tAIF (lane 2). PD150606 and
Bax inhibited the release of tAIF completely (lane 6). VDAC inhibitor, DIDS, anti-VDAC C-term
VDAC-M and a-VDAC-C recognize the intermediate amino acid sequence and C-terminus of
method was the same as panel (C). The remaining tAIF was recovered following exposure to
that PD150606, anti-VDAC, and anti-Bax antibodies prevent the release of tAIF from the miof tAIF from the mitochondria in the presence of cytosolic fraction
after removing μ- and m-calpain by DEAE-Sepharose column
chromatography. The processing of AIF was not facilitated in
1 mM Ca2+ (Fig. 6A). No tAIF was released from the mitochondria
in the absence of cytosolic proteins (Fig. 6C). Cytosolic proteins
induced the release of tAIF, suggesting that cytosolic proteins were
essential for the release of tAIF from the mitochondria. PD150606
and anti-VDAC antibody prevented the release of tAIF. On the
other hand, the antibody against Bax completely inhibited the
release of tAIF from mitochondria. VDAC inhibitor, DIDS, anti-VDAC
C-terminal antibody, and normal rabbit IgG, did not affect the
release of tAIF. The remaining tAIF in the IMS was recovered by
treating with PD150606, anti-VDAC, and anti-Bax antibodies
(Fig. 6D). These results suggested that mitochondrial m-calpain
facilitated the release of tAIF from mitochondria, and tAIF passed
through VDAC-Bax and Bax-Bax complexes.
3.8. In vitro assay of proteolytic processing of VDAC
We predicted that the conformational changes of VDAC or VDAC-
Bax complexes following their cleavage by mitochondrial m-calpain
will accelerate the release of tAIF from mitochondria. Thus, weAIF frommitochondria. Details are described in the Materials and methods section. Each
, and Bax control the release of tAIF frommitochondria, we ﬁrst activatedmitochondrial
ndria supplemented with 50 μM Ca2+. Results are representative of three independent
ncated to ∼57-kDa tAIF (open arrowhead) at 50 μM Ca2+. The processing of AIF was not
calpain is not revealed by autolysis after 50 μM Ca2+-incubation (lane 4). (C) Released
μM Ca2+ concentration, which induced the activation of mitochondrial m-calpain. We
C, and anti-Bax antibodies on releasing of tAIF from mitochondria in the presence of
phy. No releases of tAIF from themitochondria were observed in the absence of cytosolic
anti-VDAC antibodies prevented the release of tAIF (lane 3 and 4). The antibody against
inal antibody, and normal rabbit IgG did not alter the release of tAIF (lane 5, 7, and 8). a-
human VDAC, respectively. (D) Remaining tAIF in the mitochondrial IMS. Experimental
PD150606, anti-VDAC, and anti-Bax antibodies (lane 3, 4 and 6). These ﬁndings indicate
tochondrial IMS (lane 3 and 4).
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VDAC. Rat liver mitochondrial OM was incubated with partially
puriﬁed cytosolic μ-, m-calpains, mitochondrial μ- and m-calpains,
respectively. Only mitochondrial m-calpain had the ability to
truncate ∼31-kDa VDAC and the truncated VDAC was ∼23-kDa
(Fig. 7). In addition, this processing occurred in the presence of Ca2+
and was inhibited by PD150606.
3.9. Effects of Ca2+ concentration on activation of mitochondrial
m-calpain, processing of VDAC, accumulation of Bax in mitochondrial
OM, and release of tAIF from mitochondria
We next tested whether the processing of VDAC by mitochon-
drial m-calpain can be induced in isolated mitochondria. We also
examined whether this proteolysis was correlated with the
accumulation of Bax in the mitochondrial OM and the release of
tAIF from mitochondria. Isolated mitochondria of rat liver were
incubated in suspending buffer with different concentrations of
CaCl2 (0–1000 μM) at 30 °C for 1 h. After the incubation, the
proteins released from mitochondria and remaining proteins in the
mitochondria were separated by centrifugation at 10,000×g for
10 min at 4°C. We determined the activation/autolysis of mito-
chondrial m-calpain, proteolytic processing of VDAC, and accumu-
lation of Bax by western blot of the IMS and OM fractions.
The proteins released from mitochondria were used for western
blots to determine whether tAIF was release from the mitochon-
dria. We found that mitochondrial m-calpain in the IMS was
autolysed from the 75-kDa intact form to the 40-kDa autolysed
form by ≥100 μM Ca2+ (Fig. 8A). VDAC truncation occurred with
≥250 μM Ca2+ and was completely inhibited by PD150606
(Fig. 8B). An accumulation of Bax in the mitochondrial OM was
observed at ≥100 μM Ca2+ and was roughly synchronized with
the processing of VDAC. The released tAIF from the mitochondria
was detectable at concentrations as low as 20 μM Ca2+. However,
the amount increased abruptly at 100 μM Ca2+, at which point the
activation of mitochondrial m-calpain, the processing of VDAC, and
the accumulation of Bax occurred (Fig. 8D).
VDAC and mitochondria-accumulated Bax were co-immunopre-
cipitated (Fig. 8E). This showed that the processing of VDAC by
mitochondrial m-calpain facilitated the accumulation of Bax, its
binding to VDAC, and the release of tAIF from mitochondria in
response to mitochondrial Ca2+ inﬂux.Fig. 7. Proteolytic processing of VDAC bymitochondrial m-calpain. Details are described
in theMaterials andmethods section. Mitochondrial OMwas suspended in 20mM Tris–
HCl, pH 7.5, and 5 mM 2-mercaptoethanol. DEAE-Sepharose puriﬁed-cytosolic μ-, m-
calpains, and mitochondrial μ- and m-calpains (10 μg/tube) were added to the OM
preparation (30 μg/tube). Each sample was incubated for 30 min at 30 °C in the
presence or absence of 1 mM CaCl2, 5 mM EGTA, and 10 μM PD150606. Only mito-
chondrial m-calpain had the ability to truncate ∼31-kDa VDAC to ∼23-kDa truncated
form (lane 3). This processing does not occur in the absence of Ca2+ (lane 6) or in the
presence of PD150606 (lane 7). Results are representative of three independent
experiments.4. Discussion
Despite the increased interest in the localization and function of
the mitochondrial calpains, all of the mitochondrial calpains have
not been identiﬁed. Our experiments isolated a calpain 2 (m-calpain
large subunit) in the IMS of rat liver mitochondria, which was
stained with anti-m-calpain domain I and IV and was associated
with calpain small subunit. We tentatively named it mitochondrial
m-calpain. It is associated with Grp75 and plays a signiﬁcant role in
the release of tAIF from mitochondria.
Earlier we found two types of mitochondrial calpains by casein
zymography; mitochondrial μ-calpain and an unknown mitochon-
drial calpain [14,15]. In this study, the unknown mitochondrial
calpain was identiﬁed as calpain 2 (m-calpain large subunit). One
of the important ﬁndings in our experiments is that the identiﬁed
mitochondrial m-calpain is positive to anti-m-calpain domains I
and IV but not to domain III. Cloning and nucleotide sequencing of
Capn2 coding m-calpain domain III indicated that splicing variants
of m-calpain are not detected in rat liver. At present, we are trying
to identify the differences between cytosolic and mitochondrial m-
calpain using LC-MS/MS analysis.
Badugu and Garcia et al. [17] reported that μ-calpain large subunit,
but not m-calpain large subunit, contained a mitochondrial targeting
sequence in its N-terminal. One IMS import mechanism is similar to
that of mitochondrial matrix proteins and involves an N-terminal
amphipathic helical domain [37]. An additional import mechanism is
the interaction with translocase of the outer membrane (TOM)
complex with an internal sequence, and following the import of the
proteins, binds stably to chaperones or lipids within the IMS [38]. The
latter mechanism might enable mitochondrial m-calpain (m-calpain
splice variant) to be located in the mitochondria.
The interaction between mitochondrial m-calpain and Grp75
was conﬁrmed in isolated mitochondria by co-immunoprecipitation
followed by western blot analysis. Grp75 is an important molecular
chaperone belonging to the heat shock protein 70 family [39–41]. It
has multiple functions including the import into mitochondria, and
the proper folding of newly synthesized, nuclear and mitochondrial
encoded proteins. It can also respond to many forms of stress
including glucose deprivation, oxidative injury, and ultraviolet
irradiation [42]. Although the role of Grp75 for mitochondrial m-
calpain was not examined in this study, we suggest that it functions
mainly in the refolding of mitochondrial m-calpain large subunit
after translocation. This refolding is likely to be involved in the
formation of disulﬁde bonds to form functional conformations. In
the future, the relationship between several stresses on the expres-
sion of Grp75 and the activity of mitochondrial m-calpain should be
investigated.
The role of AIF nuclear translocation as caspase-independent cell
death pathway has been recently established in neuronal insults,
including retinal photoreceptor apoptosis [27,28] and cerebral
hypoxia/ischemia [16,29]. The release of mitochondrial AIF is a key
step in the signaling cascade leading to cell death in these
neurological disorders. We have demonstrated that mitochondrial
μ-calpain, which associates with ERp57, cleaves mature AIF
(∼62 kDa) and releases tAIF (∼57 kDa) from the mitochondrial IM
to the IMS [15]. This suggests that mitochondrial μ-calpain is an
initiator of the AIF-induced cell death signaling pathway. Recently,
Joshi et al. [43] demonstrated that mitochondrial μ-calpain is not
involved in the processing of AIF using SH-SY5Y neuroblastoma cells.
Considering this report, we supposed that mitochondrial μ-calpain
truncates AIF in tissue-speciﬁc or pathology-speciﬁc manners.
On the one hand, the mechanism by which tAIF is released
from the IMS to the cytosol is not fully understood under both in
vitro and in vivo conditions. We have shown that the release of
tAIF from mitochondria was inhibited by calpain inhibitor,
PD150606, during the IMS localization of tAIF, and the absence
Fig. 8. Effects of Ca2+ concentration on activation of mitochondrial m-calpain, processing of VDAC, accumulation of Bax in mitochondrial OM, and release of tAIF frommitochondria.
Details are described in the Materials and methods section. Isolated mitochondria were incubated at 30°C for 30 min with different concentrations of CaCl2 (0–1000 μM). After
incubation, each sample was centrifuged at 10,000×g for 10 min at 4 °C. Using IMS and OM fractions, we determined the activation/autolysis of mitochondrial μ-calpain in the IMS
(A), proteolytic processing of VDAC in the OM (B), and accumulation of Bax in the OM (C) by western blots. The supernatant containing released proteins from mitochondria were
used for western blots to determine the release of tAIF (D). (E) Immunoprecipitation of VDAC by anti-Bax antibody. Accumulated Bax in mitochondrial OM binds to ∼23-kDa
truncated VDAC (lane 1). Normal rabbit IgG was used as a negative control (lane 2). Results are representative of three independent experiments.
Fig. 9. Model of AIF processing and release from mitochondria. An apoptotic stimulus
leads to the inﬂux of Ca2+ into the cytosol. The prolonged increase of the intracellular
Ca2+ level leads to Ca2+ inﬂux into mitochondria, resulting in the activation of
mitochondrial μ-calpain in the IMS. Activated mitochondrial μ-calpain truncates and
releases AIF from the IM into the IMS. A further increase of mitochondrial Ca2+ level
activates mitochondrial m-calpain leading to a truncation of VDAC and association of
Bax in the OM. tAIF is then released into the cytosol through VDAC/Bax-mediated pores
or Bax/Bax-mediated pores.
1857T. Ozaki et al. / Biochimica et Biophysica Acta 1793 (2009) 1848–1859of mitochondrial μ-calpain activity. These observations suggest that
mitochondrial m-calpain plays a signiﬁcant role in the release of
tAIF to the cytosol. Furthermore, our results suggest that the
release of tAIF could be controlled not only by mitochondrial μ-
calpain but also by VDAC and Bax.
Because the antibody against VDAC prevented the release of tAIF
from the IMS, we investigated whether VDAC could be targeted for
mitochondrial m-calpain. VDAC is a key channel protein in the
mitochondrial OM that integrates cellular energy metabolism [44].
Due to its function in the release of apoptotic proteins, VDAC has
also been recognized as a key protein in mitochondria-mediated
apoptosis. VDAC has been proposed to be the target for the pro-,
anti-apoptotic Bcl-2-family proteins and hexokinase-I [45–47]. Our
results show that mitochondrial m-calpain truncates VDAC at Ca2+
concentration of not less than 250 μM, where the accumulation of
Bax in the mitochondrial OM and the release of tAIF from mito-
chondria were markedly increased. We suggest that proteolytic
processing of VDAC by mitochondrial m-calpain induces conforma-
tional changes of the VDAC complex and Bax binding to VDAC. The
estimated size of the VDAC pore is ∼2.6 nm, which is not large
enough for folded tAIF to pass through [48]. Shimizu et al. [45,49]
found that Bax directly interacts with VDAC and forms new large
pores. It has been shown that the tAIF translocation to cytosol is
abrogated in Bax-deﬁcient neurons [50] and transient overexpres-
sion of Bax was shown to trigger the release of AIF in 293T and HeLa
1858 T. Ozaki et al. / Biochimica et Biophysica Acta 1793 (2009) 1848–1859cells [51,52]. Several studies in cell-free systems using lipid vesicles
have shown that proapoptotic family members such as Bax and Bak
can homo-oligomerize to form a pore sufﬁciently large for the
release of 70-kDa molecules [53–55]. Large complexes containing
Bax and Bak have been observed on the mitochondrial OM by elec-
tron microscopy [56]. The results of other studies suggested that
proapoptotic family members can form complexes with mitochon-
drial membrane proteins such as VDAC to yield pores sufﬁciently
large to allow 100-kDa proteins to pass through [45,57].
DIDS, a VDAC inhibitor, did not affect the VDAC-Bax channel. DIDS
is known to be an anion channel blocker and a thiol cross-linker. DIDS
causes a reversible ﬂickering of VDAC into the closed state, reducing
the apparent single channel amplitude by up to 70% at 0.5 mM [58].
Our results and these data suggest that the VDAC-Bax channel is
substantially different from the VDAC channel and carries tAIF into the
cytosol regardless of a decrease in anion permeability. Thus, various
unknown components of this pore seem to interact and the tAIF-
releasing mechanism may be complicated.
In summary, we have identiﬁed mitochondrial m-calpain in the
IMS, which associates with Grp75 chaperone. Mitochondrial m-
calpain plays a signiﬁcant role in the release of tAIF into the cytosol
by proteolytic processing of VDAC (see Fig. 9). The release of AIF
appears to occur in several steps. First, mitochondrial μ-calpain
cleaves IM-integrated AIF and releases it into the IMS. Second, the
soluble tAIF in the IMS is released to the cytosol by the activation of
mitochondrial m-calpain by cleaving VDAC, and by the mitochondrial
accumulation of Bax. In this way, AIF released from the mitochondria
could be controlled not only by mitochondrial μ-calpain but also by
mitochondrial m-calpain. The results of this study provide new
insights that the inhibition of mitochondrial calpains in the IMS may
have a therapeutic potential for many disorders such as retinitis
pigmentosa/retinal degeneration and cerebral ischemia.
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